NIH Director Statement on Catalyzing the Development of Novel Alternative Methods
This report, which the ACD enthusiastically endorsed and conveyed to the agency, recommended that NIH work with the community to:
Prioritize the development and use of combinatorial NAMs
Establish resources, infrastructure, and collaborations to promote the use of interoperable, reliable, and well curated/high quality datasets produced from research using NAMs
Promote effective dissemination and interconnection of NAM technologies
Invest in comprehensive training to bolster continuous advances in development and use of NAMs
Facilitate multidisciplinary teams with expertise across technologies and the lifecy...
Source: NIH Extramural Nexus - February 9, 2024 Category: Research Authors: Mike Lauer Tags: blog Open Mike Alternatives to Animals Animal Welfare rigor Source Type: funding
Research Network to Promote Multidisciplinary Mechanistic and Translational Studies of Sickle Cell Disease Pain (U24, Clinical Trial Optional)
Funding Opportunity RFA-AT-24-001 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support a Research Network that promotes multidisciplinary mechanistic and translational studies of Sickle Cell Disease (SCD) pain. This network is expected to develop compelling research frameworks and model systems that will support interdisciplinary collaborations; initiate pilot projects to test novel mechanistic hypotheses in the high-priority research areas listed below and develop novel technologies and methodologies to study pain in the organ(s) typically impacted by SCD. To accomplish these objectives, a...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 27, 2023 Category: Research Source Type: funding
HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required)
Funding Opportunity RFA-AT-23-002 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit cooperative agreement applications to support multisite efficacy or effectiveness clinical trials of pharmacologic, nonpharmacologic, and/or multicomponent approaches for acute and/or chronic sickle cell disease (SCD) pain management, allowing continued opioid pain management as needed. However, opioid medication use alone should not be the only intervention studied. Trials supported under this initiative may also address the impact of these approaches on related psychol...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 13, 2022 Category: Research Source Type: funding
HEAL Initiative: Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain (UG3/UH3, Clinical Trials Optional)
Funding Opportunity RFA-AT-23-001 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit cooperative agreement applications to conduct multisite embedded pragmatic or implementation trials to inform the uptake of pharmacologic, nonpharmacologic, and/or multicomponent approaches for acute and/or chronic sickle cell disease (SCD) pain management in health care systems that serve the SCD population. Trials may include or allow continuation of opioid medication as needed; however opioid medication use alone should not be the only intervention studied. Trials may...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 13, 2022 Category: Research Source Type: funding
HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed)
Funding Opportunity RFA-NS-22-052 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) is part of a suite of FOAs to support the development of safe, effective, and non-addictive therapeutics to treat pain. The goal of this FOA is to support team-based research projects to develop assays, screening and early optimization work to develop a non-addictive therapeutic to treat pain. Discovery and validation of pharmacodynamic markers efficacy and pharmacokinetic/pharmacodynamic (PK/PD) studies are also responsive. The result of the project should be to advance a hit or lead to the point w...
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 22, 2022 Category: Research Source Type: funding
NCCIH Announces Availability of Frequently Asked Questions (FAQs) for HEAL Sickle Cell Disease Pain Management Funding Opportunities RFA-AT-22-004 and RFA-AT-22-005
Notice NOT-AT-22-006 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 1, 2021 Category: Research Source Type: funding
Notice of Correction to NHLBI-Specific language in RFA-AT-22-004, "HEAL Initiative: Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain (UG3/UH3, Clinical Trials Optional)"
Notice NOT-HL-22-005 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 18, 2021 Category: Research Source Type: funding
HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required)
Funding Opportunity RFA-AT-22-005 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit cooperative agreement applications to support multisite effectiveness clinical trials of pharmacologic, nonpharmacologic, and/or multicomponent approaches for acute and/or chronic sickle cell disease (SCD) pain management, allowing continued opioid pain management as needed. However, opioid medication use alone should not be the only intervention studied. Trials supported under this initiative may also address the impact of these approaches on related psychological and f...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 29, 2021 Category: Research Source Type: funding
HEAL Initiative: Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain (UG3/UH3, Clinical Trials Optional)
Funding Opportunity RFA-AT-22-004 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit cooperative agreement applications to conduct multisite embedded pragmatic or implementation trials to inform the uptake of pharmacologic, nonpharmacologic, and/or multicomponent approaches for acute and/or chronic sickle cell disease (SCD) pain management in health care systems that serve the SCD population. Trials may include or allow continuation of opioid medication as needed; however opioid medication use alone should not be the only intervention studied. Trials sup...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 29, 2021 Category: Research Source Type: funding
Notice of Intent to Publish a Funding Opportunity Announcement for HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required)
Notice NOT-AT-21-017 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 8, 2021 Category: Research Source Type: funding
Notice of Intent to Publish a Funding Opportunity Announcement for HEAL Initiative: Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain (UG3/UH3, Clinical Trials Optional)
Notice NOT-AT-21-018 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 8, 2021 Category: Research Source Type: funding
HEAL Initiative: Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed)
Funding Opportunity RFA-NS-21-015 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) is part of a suite of FOAs to support the development of safe, effective, and non-addictive therapeutics to treat pain. The goal of this FOA is to support team-based research projects to develop assays, screening and early optimization work to develop a non-addictive therapeutic to treat pain. Discovery and validation of pharmacodynamic markers efficacy and pharmacokinetic/pharmacodynamic (PK/PD) studies are also responsive. The result of the project should be to advance a hit or lead to the point w...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 11, 2021 Category: Research Source Type: funding
Notice of Technical Assistance Webinar for NHLBI Hope for Sickle Cell Disease Challenge
Notice NOT-HL-21-001 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 14, 2021 Category: Research Source Type: funding
NIH Helps Small Businesses Change the World
Did you know that
the NIH’s small business programs (SBIR and STTR) invest over 1 billion dollars into
life science and healthcare companies each year? The newly-created Small business
Education and Entrepreneurial Development (SEED) office provides grantees with many of the
valuable entrepreneurship and commercialization services we have discussed in previous blogs to help them thrive.
As our small business program has grown, we
have seen early ideas transform into improved patient access to technologies.
To celebrate these successes, the NIH has launched a new interactive mapping tool thatfeatures many of the amazi...
Source: NIH Extramural Nexus - August 13, 2020 Category: Research Authors: Mike Lauer Tags: blog Open Mike SBIR small business Source Type: funding
Sickle Pan-African Research Consortium Collaborative Sites (U01 Clinical Trial Optional)
Funding Opportunity RFA-HL-21-009 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks both applications from established sites of the Sickle Pan-African Research Consortium (SPARCO) and applications from other Sub-Saharan African nations to become the Consortiums new sites. The renewed and expanded SPARCO including a Clinical Coordinating Center (CCC), up to 3 established sites and additional satellite sites, up to 3 new sites, and the associated Sickle Africa Data Coordinating Center (SADaCC) will together constitute the Sickle Cell Disease (SCD) in Sub-Saharan Africa (SSA) Ne...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 12, 2020 Category: Research Source Type: funding
